Skip to main content
. 2020 Jun 30;12(7):1738. doi: 10.3390/cancers12071738

Figure 3.

Figure 3

IDH2 mutation monitoring in complete remission (CR). In these four cases (#A, #B, #C, #D), IDH2 mutations well correlated with the clinical response; in these patients IDH2 might be considered as a good marker for minimal residual disease (MRD).